Prosecution Insights
Last updated: November 04, 2026

Par Pharmaceutical Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Par Pharmaceutical Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, TRAN, ERIC, who is the busiest examiner with 1 pending application. The portfolio is active in 1 distinct art unit, indicating a streamlined prosecution process for the company's current filings.

This 1 to 1 ratio of pending office actions to examiners indicates that the company's immediate workload is concentrated. Since TRAN, ERIC is the 1 distinct examiner currently reviewing the company's work, the prosecution success relies on meeting the specific criteria of this official. Practitioners should focus on the 1 pending office action as the sole driver of the company's current interactions with the patent office.

The focus on 1 distinct art unit within the Biotechnology & Pharmaceuticals sector suggests a specialized technical niche. Successfully addressing the 1 pending application under TRAN, ERIC will be the primary objective for the company's current patent strategy. This focused administrative environment allows the company to dedicate significant attention to the feedback provided in the 1 pending office action.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
TRAN, ERIC 1 69.7% +19.4%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17694165 EPINEPHRINE FORMULATIONS TRAN, ERIC —

Top Art Units

Art UnitApps
1629 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17694165 EPINEPHRINE FORMULATIONS TRAN, ERIC 1629 §103 Non-Final OA — Pending Mar 14, 2022

Managing Par Pharmaceutical Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Par Pharmaceutical Inc. have?

Par Pharmaceutical Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Par Pharmaceutical Inc. applications?

Eric Tran has the most, with 1 of Par Pharmaceutical Inc.'s pending office actions.

What technology area are Par Pharmaceutical Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month